Screener
Aurinia Pharmaceuticals AUPH EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Unrealized loss on available-for-sale securities | (97) | (80) | (378) | (258) |
| Comprehensive income | $37,317 | $21,433 | $71,391 | $44,599 |
| Earnings per share | ||||
| Basic | $0.29 | $0.16 | $0.55 | $0.33 |
| Diluted | $0.28 | $0.16 | $0.53 | $0.32 |
| Shares used in computing earnings per share | ||||
| Basic | 130,081 | 134,873 | 131,221 | 136,878 |
| Diluted | 133,530 | 137,526 | 135,518 | 140,193 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's EPS (basic)?
- Aurinia Pharmaceuticals (AUPH) reported EPS (basic) of $0.29 in Q2 2026.
- How has Aurinia Pharmaceuticals's EPS (basic) changed year-over-year?
- Aurinia Pharmaceuticals's EPS (basic) increased by 81.2% year-over-year, from $0.16 to $0.29.
- What is the long-term trend for Aurinia Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's EPS (basic) has grown at a 11.4% compound annual growth rate (CAGR), from -$1.41 to $2.17.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Aurinia Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude